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Abstract 
Purpose: To determine the outcomes in regards to seizure control and foetal malformation in 
pregnant women with epilepsy not treated with antiepileptic drugs (AEDs). 
Methods: Analysis of data from the Australian Register of AEDs in Pregnancy on 148 women 
with epilepsy who were not receiving AEDs before and during at least the first 
trimester of pregnancy 
Results: Seizure control was less likely to be maintained in AED-untreated pregnancies. 
Whether AED therapy had been ceased in preparation for pregnancy, or had not been 
employed for long periods before pregnancy, made no statistically significant 
difference to seizure control outcomes, but those who ceased therapy in preparation 
for pregnancy were more likely to again be taking AED therapy by term. 
 Foetal malformation rates were reasonably similar in untreated pregnancies, and in 
treated pregnancies if pregnancies exposed to known AED teratogens (valproate and 
probably topiramate) were excluded from consideration.  
Conclusions: Leaving epilepsy untreated during pregnancy appears disadvantageous from the 
standpoint of seizure control: it also does not reduce the hazard of foetal 
malformation unless it avoids valproate or topiramate intake during pregnancy. 
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Introduction 
The extensive and continuing publicity regarding the foetal malformations associated with the use 
thalidomide by pregnant women in the 1960s made many women aware of the hazards of therapeutic 
drug intake during pregnancy. This wariness extends to antiepileptic drugs (AEDs), even though most 
women with epilepsy also appreciate the importance of maintaining optimal freedom from their 
seizures. Prior to undertaking pregnancy some women with epilepsy consider ceasing their AED 
therapy. Some may seek medical advice regarding the advantages and disadvantages of doing so. 
Others make their own unguided decisions and either reduce dosages on their own initiative or cease 
AEDs altogether 1. However, there is relatively little information as to what actually happens to 
women with epilepsy who enter pregnancy when not taking any AED therapy. 
The Australian Register of Antiepileptic Drugs in Pregnancy is concerned mainly with teratogenesis 
issues, but contains data on the behaviour during pregnancy of the seizure disorders of those enrolled 
in it. Some 8.8% of the pregnancies in women with epilepsy in the Register were not exposed to 
AEDs during the early months of pregnancy. Some were not exposed throughout pregnancy. We here 
compared what happened to the pregnancies of these untreated women with what happened to the 
pregnancies exposed to AED therapy throughout. 
 
Materials and Methods 
The Australian Pregnancy Register  
The nature of the Australian Register of Antiepileptic Drugs in Pregnancy and its method of data 
collection and storage have been described previously 2-4. The Register, which has been collecting 
data since 1999, is estimated to have captured some 8 to 9% of all Australian pregnancies in women 
with epilepsy 5. In essence, the Register has functioned by enrolling pregnant women, the great 
majority of whom had epilepsy and took AEDs, and prospectively following the outcomes of their 
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pregnancies. These women initiated their own participation in the Register’s database once they had 
become aware of its existence. All contact between the women and the Register was by means of 
telephone, with interviews on 4 occasions - at recruitment as early in pregnancy as feasible, at 7 
months of gestation, in the post-partum month and, as far as possible, one year after childbirth.  At 
each interview, in addition to material concerning the foetus, details of the patient’s epilepsy, and of 
the occurrence and type of any epileptic seizures and the antiepileptic drugs being taken and their 
dosages, were recorded. Women taking AEDs for a non-epileptic indication are also enrolled on the 
Register, however for the present paper only women with epilepsy were studied, whether or not they 
were taking AEDs during the earlier months of pregnancy. 
Ethical oversight of the Register has been the responsibility of the Ethics Research 
Committees of St. Vincent’s Hospital, Melbourne, the Monash Medical Centre, and the Royal 
Melbourne Hospital, because the Register’s site of housing has changed with time. 
 
Data analysis   
Data were exported from the Register’s database into an Excel spreadsheet for further analysis, and 
statistical significances assessed by means of confidence interval analysis. 
In the analyses, a distinction was made between the outcomes for seizure control during pregnancy in 
women with ‘active’ and with ‘inactive’ epilepsy, i.e. in women who had, and women who had not 
experienced seizures during the previous 12 months. It had been observed previously that the 
prognosis for seizure freedom during pregnancy was quite different, depending on whether or not a 
woman had suffered seizures during her pre-pregnancy year 6-8. In the present series, seizures had 
occurred during pregnancy in 79.2% of pregnancies associated with less than 1 year of pre-pregnancy 
seizure freedom, but in progressively lower proportions of those with longer periods of seizure 
freedom (in 23% of those with at least 1 year’s freedom, in 20.5% with 2 years’ freedom, in 19% with 
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3 years’ freedom, in 17.5% with 4 years’ freedom and in 17.7% with 5 or more years seizure-
freedom). 
 
Results 
Of 1720 pregnancies in women with epilepsy included in the Australian Register, 148 (8.8%) were 
not exposed to AEDs at the time of conception. Various characteristics of the pre-pregnancy 
circumstances and the pregnancies, and the associated seizure disorders in the AED untreated and 
AED treated groups, are compared in Table 1 In general, the two groups seemed reasonably similar in 
composition in relation to the parameters considered. However, the AED treatment in the untreated 
group had been changed more often before pregnancy than in the treated group (because by definition 
being in the untreated group itself often involved a treatment change, viz. withdrawal of therapy).  
Members of the untreated group were more likely to have experienced epileptic seizures of any type 
during pregnancy (56.1% versus 46.9%). There were no statistically significant differences between 
the types of seizure disorder involved, the occurrence rates of convulsive seizures at some stage 
during pregnancy, and of the behaviours of active and inactive epilepsies. Those not taking 
antiepileptic drugs were also less likely to have taken folate before pregnancy.  Foetal malformations 
were half as frequent in the untreated group as in the AED treated pregnancies, but the difference was 
not statistically significant. When pregnancies associated with continuing intake of valproate and 
topiramate, both known teratogens 9, were excluded, there was little difference in the rate of foetal 
malformations between the AED treated and untreated pregnancies. On the other hand, in comparison 
with pregnancies exposed to valproate and/or topiramate, the risk of foetal malformation was 
statistically significantly lower in the untreated pregnancies.  
Within the 148 pregnancies not treated with AEDs at the time of conception a number of features, 
mainly concerning seizure activity, were compared between the women whose seizure disorders were 
active before pregnancy and those whose disorders were inactive (Table 2). The only significant 
difference between the two groups was a considerably higher rate of seizure occurrence during 
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pregnancy in the women with already active epilepsies at entry into pregnancy (any seizures: 82.4% 
versus 29.7%; convulsive seizures: 36.5% versus 12.2%). The epilepsy history for women who had  
active epilepsy before their untreated pregnancies were of shorter mean duration (10.6 versus 14.1 
years), and by term were more often being treated with AEDs (55.4% versus 37.8%). 
There were 62 of the 148 pregnancies (41.9%) in women who had elected to cease AED treatment 
shortly prior to pregnancy. Nearly all of these women indicated that they wished to avoid drug intake 
during pregnancy. The remaining untreated pregnancies were in women with epilepsy that was either 
previously untreated or in whom treatment had been ceased well before pregnancy. Half of the 
women who were untreated in the longer term had undergone previous pregnancies. Only four of 
these 43 (9.3%) had taken AEDs in previous pregnancies. This suggested that there was a group of 
women who followed a consistent pattern of reluctance to take AEDs. The outcomes of the two 
subsets of untreated pregnancies are compared in Table 3 
Those who deliberately ceased AED treatment in preparation for pregnancy had a slightly younger 
mean age than those who had been untreated over longer periods. There were no significant 
differences between the rates of occurrence of the major types of seizure disorder in two groups, or in 
the proportions of each group who had seizures during pregnancy. More who had ceased treatment as 
a pre-pregnancy precaution were found to have resumed AED therapy by the end of pregnancy 
(56.4% versus 39.5%). The data suggested that having seizures during pregnancy in those who had 
ceased AEDs before pregnancy increased the likelihood that AED therapy would be resumed by the 
end of pregnancy (83.3% v 31.3%; R.R. = 2.67, 95% C.I. = 1.56, 4.57). The same applied for those 
with longer term non-use of AEDs (54.7% v 15.2%; R.R. = 3.61, 95% C.I. = 1.55, 8.40). 
Foetal malformation rates were too low to permit conclusions regarding differences in teratogenesis 
hazard between the two patterns of untreated pregnancies, or between treated and untreated 
pregnancies if the effects of valproate and topiramate exposure, as mentioned above, were excluded    
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Discussion  
Since the review of Schmidt 10 more than 30 years ago, a number of papers have been published 
concerning the effects of pregnancy on epileptic seizure control (e.g. 7), but almost all of these applies 
to AED-treated epilepsy. There is a paucity of quantitative data on untreated epilepsy in pregnancy 
that can be compared with the findings of the present study. So long as it is accepted that AEDs can 
prevent epileptic seizures, some outcomes of the study described are as expected, e.g. that those who 
were not taking AEDs at the outset of pregnancy would be more likely to have seizures during 
pregnancy than those who had similar degrees of seizure activity before pregnancy but continued to 
take AEDs. It might also have been anticipated that there would have been more difference than was 
found in the rates of seizure occurrence in pregnancy between those who had recently ceased 
antiepileptic drug treatment in anticipation of pregnancy and those who had not taken antiepileptic 
drugs for a longer time, if ever. 
The number of untreated pregnancies in the present study is comparatively small, relative to the 
number of treated pregnancies, though this represents the outcome of 15 years of nationwide 
voluntary data collection. To delay analysis till sufficient numbers had been accumulated to 
significantly increase the statistical power of the study would probably involve a prohibitively long 
period during which therapeutic practice might change. Because of comparatively small numbers in 
the untreated group, failure to detect statistically significant differences in some parameters studied 
may not necessarily mean that real differences do not exist, particularly when relative risk values are 
near a 95% confidence interval limit. Thus there was a statistically significant increase risk of any 
type of seizure occurring during pregnancy in the untreated group (relative risk 1.20; 95% confidence 
interval 1,03, 1.39). However in the component subsets of this group, one where seizures had 
occurred in the year before pregnancy and the other where they had not occurred, the differences did 
not achieve statistical significance. It is also possible that in some of the pregnancies that fell into the 
treated category, the women involved may not have been fully compliant with prescribed therapy. If 
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so, this may have decreased the true differences in seizure occurrence rates between the untreated and 
treated groups, when the rates in the untreated group already tended to be higher. 
The chance of having seizure during childbirth was very similar for women who had been seizure free 
compared with those who had not been seizure free in the year prior to pregnancy. The chances was 
also little different in women who had ceased antiepileptic drug intake for pregnancy and those who 
had not been taking the drugs well before the onset of pregnancy. However, the interpretation of these 
findings is confounded by the fact that more women with active epilepsies before pregnancy, and 
those who ceased the drugs intending to become pregnant, had resumed the drugs before childbirth.  
It appeared that the main determinant of the outcome regarding seizure occurrence in AED-untreated 
pregnancy was not so much the length of time before pregnancy over which no AED treatment was 
taken, but whether the women’s epilepsy was active or inactive when they entered pregnancy. If the 
epilepsy was active, women would probably tend to experience further seizures during pregnancy so 
that the disadvantages and hazards that they were already experiencing would continue. If the epilepsy 
prior to pregnancy was inactive, the women seemed to have less risk of having seizures during 
pregnancy than the women whose pre-pregnancy epilepsy was active. However, the women with 
inactive epilepsy still had about a 30% risk of seizures in pregnancy. This risk appeared greater, 
though not statistically significantly so, than the risk of seizures returning in pregnancy in the women 
with inactive pre-pregnancy epilepsy who continued to take antiepileptic medication in pregnancy. 
The untreated women with inactive epilepsy would probably have proportionately more to lose from 
having their seizures recur during pregnancy than the women with already active epilepsy, since the 
former would then face additional disadvantages, including the possibilities of physical injury during 
seizures, and possible sudden unexpected death, and would also have restrictions imposed on their 
lifestyle activities, including vehicle driving.  
 
In conclusion the experience of the present series suggested that while ceasing AEDs that are known 
teratogens, such valproate and possibly topiramate, in anticipation of pregnancy may decrease the risk 
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of having a foetal malformation, for the less teratogenic medication the risk to the foetus of continuing 
the medication may be positively outweighed by the improvement in seizures control for the mother. 
This is particularly true for women whose epilepsy was active in the year prior to the pregnancy. This 
information may help inform women with epilepsy weighing up the risks and benefits of withdrawal 
of AED therapy in preparation for pregnancy. 
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Table 1: Characteristics of the untreated and AED treated pregnant women with epilepsy, their 
epilepsies and foetal outcomes as far as malformation was concerned. The likelihood of various items 
occurring is expressed relative to that for the treated women. 
 No AEDS P<.05 AEDs R.R. or Difference 95% C.I. 
Number 148  1532   
Mean Age (years) 30.74  30.69 -0.05# -1.02, +1.12 
Referral source– neurologist 51.4%  47.9% 1.07 0.91, 1.26 
Referral  source– other medical practitioner 12.2%  15.9% 0.77 0.49, 1.20 
Pregnancy number – 1 46.6%  41.6% 1.12 0.93, 1.34 
Pregnancy number – 2 32.4%  29.6% 1.09 0.86, 1.40 
Pregnancy number – 3 11.5%  16.1% 0.71 0.45, 1.49 
Pregnancy number – 4 6.1%  7.1% 0.85 0.44, 1.65 
Pregnancy number - >4 3.4%  5.4% 0.62 0.25, 1.49 
Pregnancies 1 and 2 combined 79.1% > 73.1% 1.11 1.01,1.21 
Assisted fertilisation involved 5.4%  5.8% 0.93 0.43, 1.68 
Previous malformed offspring (N=79, 894) 2.5%  4.8% 0.53 0.13, 2.13 
Previous neonatal deaths (N=79, 894) 1.3%  0.8% 1.62 0.20, 12.97 
Epilepsy duration ( mean in years) 12.3 < 14.1 -1.80# -3.25, -0.35 
Epilepsy type – partial 44.6%  49.0% 0.91 0.76, 1.10 
Epilepsy type – generalised 45.9%  42.5% 1.08 0.90, 1.30 
Epilepsy type – uncertain 9.5%  8.6% 1.11 0.65, 1.07 
AED change before pregnancy 41.9% > 14.2% 3.03 2.42, 3.79 
Preconception folate intake 65.5% < 70.8% 0.85 0.75, 0.98 
Seizures during pregnancy – any 56.1% > 46.9% 1.20 1.03, 1.39 
Seizures during pregnancy – convulsive 24.3%  18.9% 1.29 0.95, 1.74) 
Active epilepsy before pregnancy 50.0%  43.6% 1.15 0.97, 1.36 
Seizures during pregnancy – any 82.4%  79.1% 1.04 0.93, 1.16 
Seizures during pregnancy – convulsive 36.5%  32.8% 1.13 0.81, 1.53 
Seizures during birth 2.7%  3.6% 0.75 0.18, 3.12 
Inactive epilepsy before pregnancy 50.0%  56.4% 0.89 0.75, 1.05 
Seizures during pregnancy – any 29.7%  21.9% 1.36 0.94,1.97 
Seizures during pregnancy – convulsive 12.2%  8.2% 1.48 0.77, 2.84 
Seizures during birth 3.4%  0.9% 2.92 0.63, 13.50 
Malformed foetus 3.4%  7.1% 0.47 0.20, 1.15 
Malformed foetus @ 3.4%  4.5% 0.74 0.30, 1.84 
Malformed foetus $ 3.4% < 12.1% 0.28 0.11, 0.68 
# A difference, not a R.R. value          @ Pregnancies exposed to VPA and TPM excluded    $ pregnancies exposed 
to VPA or TPM 
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Table 2: Comparisons between women with active and inactive epilepsies that were not treated with 
AEDs, at least in earlier pregnancy. The likelihood (R.R.) of various items occurring in the active 
epilepsy group is expressed relative to that for the women with inactive epilepsies. 
 Active 
Epilepsy 
P<.05 Inactive 
Epilepsy 
R.R or 
Difference 
95% C.I. 
Number 74  74   
Mean Age (years) 30.1  31.4 -1.30 # -2.85, 0.25 
Referral source– neurologist 54.1%  48.6% 1.11 0.81, 1.52 
Referral  source– other medical 16.2%  8.1% 2.00 0.79, 5.05 
Pregnancy numbers – 1 or 2 78.4%  79.7% 0.98 0.83, 1.16 
Pre-conception folate intake 59.5%  74.3% 0.80 0.64, 1.01 
Epilepsy – partial 47.3%  41.9% 1.13 0.79, 1.62 
Epilepsy-generalised 41.9%  50.0% 0.84 0.59, 1.19 
Epilepsy-type uncertain 10.8%  8.3% 1.30 0.47, 3.55 
Epilepsy duration (mean in years) 10.6 < 14.1 -3.50 # -6.54, +0.46 
Seizures during pregnancy – any 82.4% > 29.7% 4.00 2.39, 6.70 
Seizures during pregnancy – convulsive 36.5% > 12.2% 3.00 1.52, 5.93 
Seizures during birth 2.7%  2.7% 1.00 0.14, 6.91 
Taking AEDs by 7 months 53.1% > 29.7% 1.79 1.18, 2.72 
Taking AEDs by term 55.4% > 37.8% 1.46 1.03, 2.09 
Taking AEDs by term – had seizures 51.2%  57.1.4% 0.90 0.58, 1.39 
Foetal Malformations 2.7%  4.1% 0.67 0.11, 3.87 
 
# = a difference, not a RR 
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Table 3.Comparison of various differences between women who ceased AEDs in preparation for 
pregnancy, and those who were not taking AEDs well before the commencement of pregnancy 
 Came off 
AEDS P<.05
Not on 
AEDS 
R.R. or 
Difference 95% C.I. 
Number 62  86   
Mean Age (years) 29.7 < 31.5 -1.80 # -3.36, -0.24 
Referral source– neurologist 51.6%  51.2% 1.01 0.73, 1.39 
Referral  source– other medical 9.7%  14.0% 0.69 0.28, 1.75 
Pregnancy numbers – 1 or 2 82.3%  76.7% 1.07 0.91, 1.26 
Pre-conception folate intake 72.6%  60.5% 1.20 0.95, 1.51 
Pre-pregnancy active epilepsy 45.2%  47.7% 0.95 0.67, 1.35 
Epilepsy – partial 45.2%  44.2% 1.02 0.71, 1.47 
Epilepsy-generalised 43.55%  47.6% 0.91 0.64, 1.31 
Epilepsy-type uncertain 11.35%  3.5% 3.24 0.87, 12.03 
Epilepsy duration (mean, in years) 12.9  11.9 +0.9 # -2.23, +4.03 
Seizures during pregnancy – any 48.4%  61.6% 0.79 0.58, 1.07 
Seizures during pregnancy – convulsive 21.0%  26.7% 0.78 0.43, 1.42 
Seizures during birth 3.2%  2.3% 1.39 0.20, 9.58 
Taking AEDs by 7 months 43.5%  35.7% 1.29 0.86, 1.95 
Taking AEDs by term 56.4% > 39.5% 1.43 1.02, 2.01 
Taking AEDs by term – had pregnancy 
seizures 
83.3% > 54.7% 1.52 1.14, 2.04 
Taking AEDs by term – no pregnancy 
seizures 
31.3%  15.2% 2.06 0.79, 5.37 
Foetal Malformations 1.6%  4.7% 0.35 0.04, 3.03 
 
# = a difference, not a RR 
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Highlights 
• Some women with epilepsy cease AED therapy shortly before and during pregnancy  
• Some others have taken no AEDs since well before pregnancy 
• Seizure control was worse if seizures occurred in pre-pregnancy year 
• Excepting VPA and TPX, avoiding AEDs does not reduce malformation risk  
 
